[go: up one dir, main page]

PE20130309A1 - Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p) - Google Patents

Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p)

Info

Publication number
PE20130309A1
PE20130309A1 PE2012002520A PE2012002520A PE20130309A1 PE 20130309 A1 PE20130309 A1 PE 20130309A1 PE 2012002520 A PE2012002520 A PE 2012002520A PE 2012002520 A PE2012002520 A PE 2012002520A PE 20130309 A1 PE20130309 A1 PE 20130309A1
Authority
PE
Peru
Prior art keywords
alkyl
povidone
sorbitol
composition
phosphate
Prior art date
Application number
PE2012002520A
Other languages
English (en)
Inventor
Colleen Ruegger
Michael Ambuhl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130309(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20130309A1 publication Critical patent/PE20130309A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE: A) UN MODULADOR DEL RECEPTOR S1P DE FORMULA (Y), DONDE Z ES H, ALQUILO C1-6, ALQUENILO C2-6, ALQUINILO C2-6, FENILO ENTRE OTROS; R1Z ES OH, ACILOXILO, ENTRE OTROS; R2Z Y R3Z SON INDEPENDIENTEMENTE H, ALQUILO C1-4, O ACILO; B) UNO O MAS DE LOS SIGUIENTES EXCIPIENTES: (i) RELLENOS TALES COMO, MANITOL, SORBITOL, ENTRE OTROS; (ii) AGLUTINANTES TALES COMO POVIDONA, L-HPC, ENTRE OTROS; (iii) DESINTEGRANTES TALES COMO CROSPOVIDONA, SILICATO DE CALCIO, ENTRE OTROS; (iv) LUBRICANTES TALES COMO ACEITE MINERAL, L-LEUCINA, ENTRE OTROS; (v) REGULADORES TALES COMO DIOXIDO DE SILICIO COLOIDAL Y TALCO; (vi) FORMADORES DE MATRIZ TALES COMO ALMIDON, POVIDONA, ENTRE OTROS; (vii) PLASTIFICANTES TALES COMO SORBITOL, SEBACATO DE DIBUTILO Y PEG 400; (viii) AGENTES SABORIZANTES TALES COMO MENTOL Y TUTI FRUTI; (ix) EDULCORANTES TALES COMO SUCRALOSA Y SACARINA DE SODIO. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE ESCLEROSIS MUTIPLE, MIOCARDITIS VIRAL, CARCINOMA
PE2012002520A 2007-10-12 2008-10-10 Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p) PE20130309A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97948207P 2007-10-12 2007-10-12

Publications (1)

Publication Number Publication Date
PE20130309A1 true PE20130309A1 (es) 2013-03-30

Family

ID=40032615

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008001756A PE20090799A1 (es) 2007-10-12 2008-10-10 Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p)
PE2012002520A PE20130309A1 (es) 2007-10-12 2008-10-10 Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008001756A PE20090799A1 (es) 2007-10-12 2008-10-10 Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p)

Country Status (32)

Country Link
US (6) US8673918B2 (es)
EP (7) EP3733161A1 (es)
JP (2) JP6034000B2 (es)
KR (3) KR101710845B1 (es)
CN (1) CN101820916A (es)
AR (1) AR068986A1 (es)
AU (1) AU2008310846C1 (es)
BR (1) BRPI0818161B8 (es)
CA (2) CA2925175A1 (es)
CL (1) CL2008003003A1 (es)
CO (1) CO6270342A2 (es)
DK (1) DK2952177T3 (es)
EC (1) ECSP10010169A (es)
ES (2) ES2545361T3 (es)
HR (1) HRP20150838T1 (es)
HU (2) HUE027696T2 (es)
IL (3) IL204514B (es)
JO (2) JOP20080436B1 (es)
MA (1) MA31799B1 (es)
MX (1) MX337152B (es)
MY (1) MY159358A (es)
NZ (1) NZ600355A (es)
PE (2) PE20090799A1 (es)
PL (2) PL2465492T3 (es)
PT (2) PT2952177T (es)
RU (1) RU2010118457A (es)
SG (2) SG187458A1 (es)
SI (2) SI2952177T1 (es)
TN (1) TN2010000136A1 (es)
TW (1) TW200927142A (es)
WO (1) WO2009048993A2 (es)
ZA (1) ZA201001819B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170246T4 (hr) 2008-03-17 2020-02-07 Actelion Pharmaceuticals Ltd. Režim doziranja za selektivni agonist s1p1-receptora
WO2010020610A1 (en) * 2008-08-18 2010-02-25 Novartis Ag Compounds for the treatment of peripheral neuropathies
SI4098256T1 (sl) * 2008-12-22 2025-06-30 Novartis Ag Režim odmerjanja za agonist receptorja s1p
PL2379069T3 (pl) 2008-12-22 2015-08-31 Novartis Ag Schemat dawkowania agonisty receptora S1P
EA201291097A1 (ru) * 2010-04-22 2013-04-30 Рациофарм Гмбх Финголимод в форме гранулированного расплава
WO2011131369A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod in the form of a solid solution
CN101973898B (zh) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
PT2661261T (pt) * 2011-01-07 2019-10-25 Novartis Ag Formulações imunossupressoras.
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
ES2388273B1 (es) * 2011-03-16 2013-10-01 Consejo Superior De Investigaciones Científicas (Csic) Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
CA2852142A1 (en) * 2011-10-21 2013-04-25 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP2014129238A (ja) * 2012-12-28 2014-07-10 Lion Corp エトドラク含有固形製剤
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2996681B1 (en) * 2013-05-13 2019-12-18 Synthon B.V. Pharmaceutical composition comprising fingolimod
US20160128951A1 (en) 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
US20150141520A1 (en) * 2013-11-18 2015-05-21 Chandrasekhar Kandi Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
RS59534B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
CN106163502B (zh) * 2014-04-10 2020-12-01 诺华股份有限公司 免疫抑制剂配方
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
MX391191B (es) * 2014-11-17 2025-03-21 Context Biopharma Inc Composiciones de liberación extendida de onapristona y métodos.
AU2016209466A1 (en) * 2015-01-20 2017-08-10 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
TW201713343A (zh) * 2015-04-28 2017-04-16 安斯泰來製藥股份有限公司 經口投與用醫藥組成物
MX389824B (es) 2015-08-12 2025-03-20 Incyte Holdings Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
RU2639424C2 (ru) * 2015-09-15 2017-12-21 Закрытое Акционерное Общество "Биокад" Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза
BR112018006648A2 (pt) * 2015-10-02 2018-10-23 Mylan Inc. formulações estáveis de fingolimode
IL262488B (en) * 2016-04-22 2022-08-01 Incyte Corp lsdi inhibitor formulations
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
WO2020006073A1 (en) 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
EP3862318A4 (en) 2018-10-05 2022-06-15 Fuji Chemical Industry Co., Ltd. Porous silica particle composition
KR102858772B1 (ko) * 2021-04-14 2025-09-11 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제를 포함하는 직접 타정용 약제학적 조성물
EP4633611A1 (en) 2022-12-12 2025-10-22 Synthon B.V. Pharmaceutical composition of siponimod

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126658T3 (es) * 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
ES2171191T3 (es) 1994-08-22 2002-09-01 Mitsubishi Pharma Corp Compuesto de benceno y uso medicinal del mismo.
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
SI0812588T1 (en) 1995-12-28 2005-02-28 Mitsubishi Pharma Corporation Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder
DK0990440T3 (da) 1997-02-27 2009-02-23 Novartis Ag Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid
SI1002792T1 (en) 1997-04-04 2004-12-31 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
NZ523554A (en) 2000-07-13 2004-12-24 Sankyo Co Amino alcohol derivatives
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
CA2460640C (en) 2001-09-27 2011-03-29 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
KR101003877B1 (ko) 2002-09-19 2010-12-30 교린 세이야꾸 가부시키 가이샤 아미노알코올 유도체와 그 부가염 및 면역 억제제
CA2515574C (en) 2003-02-18 2012-03-13 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivative, salt thereof, and modulator of s1p receptor
EP2769713A1 (en) * 2003-04-08 2014-08-27 Novartis AG Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
FR2854549B1 (fr) 2003-05-06 2005-06-24 Actis Ets Tete pour l'equipement d'un bras de robot destine a realiser une operation d'ebavurage ou de cardage
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
DE602004027045D1 (de) 2003-06-24 2010-06-17 Univ Connecticut Verfahren zur hemmung der gefässpermeabilität und apoptose
AU2004268052B2 (en) 2003-08-28 2009-11-19 Novartis Ag Aminopropanol derivatives
CA2539033C (en) * 2003-09-12 2013-03-05 Neuronova Ab Treatment of disease or injury of the nervous system with fty720
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
WO2006102611A2 (en) 2005-03-24 2006-09-28 The Ohio State University Research Foundation Therapeutic agents for the treatment of leukemia
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
RU2487703C2 (ru) 2006-09-26 2013-07-20 Новартис Аг Фармацевтические композиции, включающие модулятор s1р

Also Published As

Publication number Publication date
AR068986A1 (es) 2009-12-23
KR101600098B1 (ko) 2016-03-04
CL2008003003A1 (es) 2009-05-15
IL204514B (en) 2018-01-31
JOP20210187A1 (ar) 2023-01-30
US20160296481A1 (en) 2016-10-13
AU2008310846B2 (en) 2012-06-21
US20170151195A1 (en) 2017-06-01
IL255737B (en) 2020-10-29
SI2465492T1 (sl) 2015-12-31
AU2008310846A1 (en) 2009-04-16
US20140142192A1 (en) 2014-05-22
US8673918B2 (en) 2014-03-18
WO2009048993A2 (en) 2009-04-16
CO6270342A2 (es) 2011-04-20
BRPI0818161B1 (pt) 2020-12-22
HUE053835T2 (hu) 2021-07-28
DK2952177T3 (da) 2021-04-26
US20170368001A1 (en) 2017-12-28
RU2016138157A (ru) 2018-12-13
IL277999A (en) 2020-11-30
EP2952177A1 (en) 2015-12-09
EP2952177B1 (en) 2021-01-20
MX2010003925A (es) 2010-05-05
PE20090799A1 (es) 2009-07-20
ES2864671T3 (es) 2021-10-14
JP6034000B2 (ja) 2016-11-30
TW200927142A (en) 2009-07-01
EP2209493A2 (en) 2010-07-28
EP2465492B1 (en) 2015-07-01
CA2699788A1 (en) 2009-04-16
EP3733161A1 (en) 2020-11-04
CN101820916A (zh) 2010-09-01
EP2653154A1 (en) 2013-10-23
KR101710845B1 (ko) 2017-02-27
AU2008310846C1 (en) 2022-10-06
SG187458A1 (en) 2013-02-28
PL2952177T3 (pl) 2021-07-19
TN2010000136A1 (en) 2011-09-26
HK1213768A1 (en) 2016-07-15
US20150165046A1 (en) 2015-06-18
US20100267675A1 (en) 2010-10-21
SG10201800085XA (en) 2018-02-27
ES2545361T3 (es) 2015-09-10
MA31799B1 (fr) 2010-10-01
MY159358A (en) 2016-12-30
PT2465492E (pt) 2015-10-15
WO2009048993A3 (en) 2010-05-06
ECSP10010169A (es) 2010-06-29
PL2465492T3 (pl) 2015-11-30
BRPI0818161B8 (pt) 2021-05-25
NZ600355A (en) 2013-02-22
CA2699788C (en) 2016-06-14
JP2015091822A (ja) 2015-05-14
KR20170021904A (ko) 2017-02-28
PT2952177T (pt) 2021-04-26
RU2016138157A3 (es) 2020-02-10
ZA201001819B (en) 2010-12-29
BRPI0818161A2 (pt) 2017-05-16
HRP20150838T1 (hr) 2015-11-06
EP3120833A1 (en) 2017-01-25
KR20160025633A (ko) 2016-03-08
EP3733162A1 (en) 2020-11-04
HUE027696T2 (en) 2016-10-28
IL255737A (en) 2018-01-31
JOP20080436B1 (ar) 2023-03-28
EP2465492A1 (en) 2012-06-20
MX337152B (es) 2016-02-15
KR20100091179A (ko) 2010-08-18
US9399066B2 (en) 2016-07-26
CA2925175A1 (en) 2009-04-16
JP2011500583A (ja) 2011-01-06
RU2010118457A (ru) 2011-11-20
SI2952177T1 (sl) 2021-07-30

Similar Documents

Publication Publication Date Title
PE20130309A1 (es) Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p)
ES2477940T3 (es) Imidazoles condensados y composiciones que los incluyen para el tratamiento de enfermedades parasitarias tales como por ejemplo malaria
PE20090159A1 (es) COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
ECSP11011512A (es) Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos
MA37834A1 (fr) Analogues de pyridazine 1,4-disubstituée et procédés de traitement de troubles liés à une déficience en smn
PE20090042A1 (es) Analogos de ciclopamina
NI200800290A (es) Moduladores bencimidazólicos de vr1
PE20190501A1 (es) Moduladores nmda espiro-lactam y metodos de uso de los mismos
CL2007003821A1 (es) Compuestos derivados de isoquinolina o isoquinolinona sustituidos con cicloalquilamina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades asociadas con la rho-quinasa y/o la fosforilacion mediada por la rho-quinasa de la cadena ligera de miosina, tales como hipertension, retinopatia, glaucoma, alzheimer, sida entre otras.
PE20190503A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190500A1 (es) Moduladores del receptor nmda spiro-lactam y uso de los mismos
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
GT200700103A (es) Compuestos biciclocarboxiamida sustituidos
NO20082174L (no) 3,5-disubstituerte fenylpiperidiner som modulatorer av dopamin-neurotransmisjon
MA37142A2 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
PE20190504A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
AR078756A1 (es) Moduladores alostericos positivos (map)
CR20110255A (es) Nuevos compuestos 578
AR074817A1 (es) Dihidropiridona-amidas como moduladores de p2x7
PH12012501853A1 (en) Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
PE20190502A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
MA38854A1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten

Legal Events

Date Code Title Description
FC Refusal